

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 June 2022 (02.06.2022)



(10) International Publication Number
WO 2022/111500 A1

(51) International Patent Classification:

C07D 207/12 (2006.01) A61P 11/00 (2006.01)
A61K 31/40 (2006.01) A61P 17/00 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CN2021/132671

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:

24 November 2021 (24.11.2021)

Published:

— with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2020/131836

26 November 2020 (26.11.2020) CN

(71) Applicant: **REZUBIO PHARMACEUTICALS CO., LTD** [CN/CN]; 36 Doukou Road, Building #1, Ste 301, Zhuhai, Guangdong 519000 (CN).


(72) Inventors: **XIONG, Yusheng**; 36 Doukou Road, Building #1, Ste 301, Zhuhai, Guangdong 519000 (CN). **GUAN, Hongping**; 36 Doukou Road, Building #1, Ste 301, Zhuhai, Guangdong 519000 (CN).

(74) Agent: **INNOPAT INTELLECTUAL PROPERTY CO., LTD.**; 6/F, Nanping Group Building, Pinglan Road, Nanping, Zhuhai, Guangdong 519060 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTICHOLINERGIC AGENTS



(57) Abstract: Compounds shown in Formula (I), pharmaceutical compositions, and methods of using related to muscarinic acetylcholine receptors. The compounds herein are typically muscarinic acetylcholine receptor antagonists, such as M₃ antagonists, which can be used for treating a variety of disorders, conditions or diseases such as hyperhidrosis.

WO 2022/111500 A1